Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2022-02-04 02:32:15 UTC |
---|
NP-MRD ID | NP0000919 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Inosine |
---|
Description | Inosine, also known as hypoxanthosine or inotin, belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Inosine is formed when hypoxanthine is attached to a ribose ring a beta-N9-glycosidic bond. Inosine is an intermediate in the degradation of purines and purine nucleosides to uric acid. Inosine is also an intermediate in the purine salvage pathway. Inosine occurs in the anticodon of certain transfer RNA molecules and is essential for proper translation of the genetic code in wobble base pairs. Inosine exists in all living species, ranging from bacteria to plants to humans. Inosine participates in a number of enzymatic reactions. In particular, inosine can be biosynthesized from inosinic acid through its interaction with the enzyme known as cytosolic purine 5'-nucleotidase. In addition, inosine can be converted into hypoxanthine and ribose 1-phosphate through its interaction with the enzyme known as purine nucleoside phosphorylase. Altered levels of inosine have also been associated with purine nucleoside phosphorylase deficiency and xanthinuria type I, both of which are inborn errors of metabolism. Animal studies have suggested that inosine has neuroprotective properties. It has been proposed as a potential treatment for spinal cord injury (PMID: 16317421 ) And for administration after stroke, as inosine appears to induce axonal rewiring (PMID: 12084941 ). After ingestion, inosine is metabolized into uric acid, which has been found to be a natural antioxidant and peroxynitrite scavenger. As such, inosine may have potential benefits to patients with multiple sclerosis and Parkinson’s disease (PMID: 19425822 ). Inosine can also be produced by gut bacteria and appears to have a number of beneficial effects. Inosine, has been shown to activate peroxisome proliferator-activated receptor (PPAR)-gamma signaling in human colon epithelial cells. Furthermore, exogenous treatment of inosine has been found to protect against DSS-induced colitis in rodents by improving adenosine 2A receptor (A2AR)/PPAR-gamma-dependent mucosal barrier functions (PMID: 33820558 ). Microbiome-derived inosine has also been shown to modulate the response to checkpoint inhibitor immunotherapy in cancer models. In particular, decreased gut barrier function induced by immunotherapy increases systemic translocation of bacterially derived inosine and activates antitumor T cells. The effect of inosine is dependent on T cell expression of the adenosine A2A receptor and requires co-stimulation. Inosine appears to have other roles in non-mammalian system. For instance, it has been found to be an important feed stimulant by itself or in combination with certain amino acids in some species of farmed fish. For example, inosine and inosine-5-monophosphate have been reported as specific feeding stimulants for turbot fry, (Scophthalmus maximus) and Japanese amberjack. |
---|
Structure | OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C(O)N=CN=C12 InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1 |
---|
Synonyms | Value | Source |
---|
9-beta-D-Ribofuranosyl-9H-purin-6-ol | ChEBI | 9-beta-D-Ribofuranosylhypoxanthine | ChEBI | Hypoxanthine D-riboside | ChEBI | Hypoxanthosine | ChEBI | i | ChEBI | Inosin | ChEBI | Inosina | ChEBI | Inosinum | ChEBI | Inotin | Kegg | 9-b-D-Ribofuranosyl-9H-purin-6-ol | Generator | 9-Β-D-ribofuranosyl-9H-purin-6-ol | Generator | 9-b-D-Ribofuranosylhypoxanthine | Generator | 9-Β-D-ribofuranosylhypoxanthine | Generator | (-)-Inosine | HMDB | 1,9-Dihydro-9-b-D-ribofuranosyl-6H-purin-6-one | HMDB | 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one | HMDB | 1,9-Dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one | HMDB | 9-b-D-Ribofuranosyl-hypoxanthine | HMDB | 9-beta-D-Ribofuranosyl-hypoxanthine | HMDB | 9-beta-delta-Ribofuranosyl-hypoxanthine | HMDB | 9-beta-delta-Ribofuranosylhypoxanthine | HMDB | 9beta-D-Ribofuranosylhypoxanthine | HMDB | 9beta-delta-Ribofuranosylhypoxanthine | HMDB | Atorel | HMDB | beta-D-Ribofuranoside hypoxanthine-9 | HMDB | beta-delta-Ribofuranoside hypoxanthine-9 | HMDB | beta-Inosine | HMDB | HXR | HMDB | Hypoxanthine 9-beta-D-ribofuranoside | HMDB | Hypoxanthine 9-beta-delta-ribofuranoside | HMDB | Hypoxanthine nucleoside | HMDB | Hypoxanthine ribonucleoside | HMDB | Hypoxanthine riboside | HMDB | Hypoxanthine-9 beta-D-ribofuranoside | HMDB | Hypoxanthine-9 beta-delta-ribofuranoside | HMDB | Hypoxanthine-9-beta-D-ribofuranoside | HMDB | Hypoxanthine-9-beta-delta-ribofuranoside | HMDB | Hypoxanthine-9-D-ribofuranoside | HMDB | Hypoxanthine-9-delta-ribofuranoside | HMDB | Hypoxanthine-ribose | HMDB | Indole-3-carboxaldehyde | HMDB | Ino | HMDB | Inosie | HMDB | Iso-prinosine | HMDB | Oxiamin | HMDB | Panholic-L | HMDB | Pantholic-L | HMDB | Ribonosine | HMDB | Selfer | HMDB | Trophicardyl | HMDB |
|
---|
Chemical Formula | C10H12N4O5 |
---|
Average Mass | 268.2261 Da |
---|
Monoisotopic Mass | 268.08077 Da |
---|
IUPAC Name | 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one |
---|
Traditional Name | inosine |
---|
CAS Registry Number | 58-63-9 |
---|
SMILES | OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O |
---|
InChI Identifier | InChI=1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1 |
---|
InChI Key | UGQMRVRMYYASKQ-KQYNXXCUSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, simulated) | Ahselim | | | 2022-02-04 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Species Where Detected | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Purine nucleosides |
---|
Sub Class | Not Available |
---|
Direct Parent | Purine nucleosides |
---|
Alternative Parents | |
---|
Substituents | - Purine nucleoside
- Glycosyl compound
- N-glycosyl compound
- 6-oxopurine
- Hypoxanthine
- Pentose monosaccharide
- Purinone
- Imidazopyrimidine
- Purine
- Pyrimidone
- Pyrimidine
- Monosaccharide
- N-substituted imidazole
- Vinylogous amide
- Tetrahydrofuran
- Heteroaromatic compound
- Azole
- Imidazole
- Secondary alcohol
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Alcohol
- Organonitrogen compound
- Organic nitrogen compound
- Organooxygen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Primary alcohol
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 218 °C | Not Available | Boiling Point | 732.82 °C. @ 760.00 mm Hg (est) | The Good Scents Company Information System | Water Solubility | 15.8 mg/mL | Yalkowsky, S. H., & Dannenfelser, R. M. (1992). Aquasol database of aqueous solubility. College of Pharmacy, University of Arizona, Tucson, AZ, 189. | LogP | -2.10 | Hansch CH, Leo A and Hoekman DH. "Exploring QSAR: Hydrophobic, Electronic, and Steric Constraints. Volume 1" ACS Publications (1995). |
|
---|
Predicted Properties | |
---|
General References | - Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Eells JT, Spector R: Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma. Neurochem Res. 1983 Nov;8(11):1451-7. [PubMed:6656991 ]
- Nakayama Y, Kinoshita A, Tomita M: Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. Theor Biol Med Model. 2005 May 9;2:18. [PubMed:15882454 ]
- Chantin C, Bonin B, Boulieu R, Bory C: Liquid-chromatographic study of purine metabolism abnormalities in purine nucleoside phosphorylase deficiency. Clin Chem. 1996 Feb;42(2):326-8. [PubMed:8595732 ]
- Castro-Gago M, Cid E, Trabazo S, Pavon P, Camina F, Rodriguez-Segade S, Einis Punal J, Rodriguez-Nunez A: Cerebrospinal fluid purine metabolites and pyrimidine bases after brief febrile convulsions. Epilepsia. 1995 May;36(5):471-4. [PubMed:7614924 ]
- Rodriguez-Nunez A, Camina F, Lojo S, Rodriguez-Segade S, Castro-Gago M: Concentrations of nucleotides, nucleosides, purine bases and urate in cerebrospinal fluid of children with meningitis. Acta Paediatr. 1993 Oct;82(10):849-52. [PubMed:8241644 ]
- Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC: Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16303-8. Epub 2002 Nov 25. [PubMed:12451183 ]
- Nakao T, Nagai F, Nakao M: Posttransfusion viability of rabbit erythrocytes preserved in a medium containing inosine, adenine, and isoosmotic sucrose. Vox Sang. 1982;42(4):217-22. [PubMed:7090336 ]
- Harkness RA, Lund RJ: Cerebrospinal fluid concentrations of hypoxanthine, xanthine, uridine and inosine: high concentrations of the ATP metabolite, hypoxanthine, after hypoxia. J Clin Pathol. 1983 Jan;36(1):1-8. [PubMed:6681617 ]
- Hsiao G, Lin KH, Chang Y, Chen TL, Tzu NH, Chou DS, Sheu JR: Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1998-2004. Epub 2005 Jun 23. [PubMed:15976325 ]
- Jabs CM, Sigurdsson GH, Neglen P: Plasma levels of high-energy compounds compared with severity of illness in critically ill patients in the intensive care unit. Surgery. 1998 Jul;124(1):65-72. [PubMed:9663253 ]
- Fazekas L, Horkay F, Kekesi V, Huszar E, Barat E, Fazekas R, Szabo T, Juhasz-Nagy A, Naszlady A: Enhanced accumulation of pericardial fluid adenosine and inosine in patients with coronary artery disease. Life Sci. 1999;65(10):1005-12. [PubMed:10499868 ]
- Mattle HP, Lienert C, Greeve I: [Uric acid and multiple sclerosis]. Ther Umsch. 2004 Sep;61(9):553-5. [PubMed:15493114 ]
- Fukumori Y, Takeda H, Fujisawa T, Ushijima K, Onodera S, Shiomi N: Blood glucose and insulin concentrations are reduced in humans administered sucrose with inosine or adenosine. J Nutr. 2000 Aug;130(8):1946-9. [PubMed:10917906 ]
- Burger DM, Kraayeveld CL, Meenhorst PL, Mulder JW, Hoetelmans RM, Koks CH, Beijnen JH: Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex. Pharm World Sci. 1995 Nov 24;17(6):218-21. [PubMed:8597780 ]
- Mabley JG, Rabinovitch A, Suarez-Pinzon W, Hasko G, Pacher P, Power R, Southan G, Salzman A, Szabo C: Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol Med. 2003 Mar-Apr;9(3-4):96-104. [PubMed:12865945 ]
- Yamamoto T, Moriwaki Y, Cheng J, Takahashi S, Tsutsumi Z, Ka T, Hada T: Effect of inosine on the plasma concentration of uridine and purine bases. Metabolism. 2002 Apr;51(4):438-42. [PubMed:11912550 ]
- Kurtz TW, Kabra PM, Booth BE, Al-Bander HA, Portale AA, Serena BG, Tsai HC, Morris RC Jr: Liquid-chromatographic measurements of inosine, hypoxanthine, and xanthine in studies of fructose-induced degradation of adenine nucleotides in humans and rats. Clin Chem. 1986 May;32(5):782-6. [PubMed:3698269 ]
- Niwa T, Takeda N, Yoshizumi H: RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int. 1998 Jun;53(6):1801-6. [PubMed:9607216 ]
- Osborne WR, Hammond WP, Dale DC: Human cyclic hematopoiesis is associated with aberrant purine metabolism. J Lab Clin Med. 1985 Apr;105(4):403-9. [PubMed:3981053 ]
- Liu F, You SW, Yao LP, Liu HL, Jiao XY, Shi M, Zhao QB, Ju G: Secondary degeneration reduced by inosine after spinal cord injury in rats. Spinal Cord. 2006 Jul;44(7):421-6. doi: 10.1038/sj.sc.3101878. Epub 2005 Nov 29. [PubMed:16317421 ]
- Chen P, Goldberg DE, Kolb B, Lanser M, Benowitz LI: Inosine induces axonal rewiring and improves behavioral outcome after stroke. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):9031-6. doi: 10.1073/pnas.132076299. [PubMed:12084941 ]
- Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H: The treatment of multiple sclerosis with inosine. J Altern Complement Med. 2009 Jun;15(6):619-25. doi: 10.1089/acm.2008.0513. [PubMed:19425822 ]
- Li D, Feng Y, Tian M, Ji J, Hu X, Chen F: Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARgamma signaling activation. Microbiome. 2021 Apr 5;9(1):83. doi: 10.1186/s40168-021-01028-7. [PubMed:33820558 ]
- Stegmann KM, Dickmanns A, Gerber S, Nikolova V, Klemke L, Manzini V, Schlosser D, Bierwirth C, Freund J, Sitte M, Lugert R, Salinas G, Meister TL, Pfaender S, Gorlich D, Wollnik B, Gross U, Dobbelstein M: The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Res. 2021 Sep;302:198469. doi: 10.1016/j.virusres.2021.198469. Epub 2021 Jun 6. [PubMed:34090962 ]
|
---|